
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA® December 31, 2020 LYON, France – NETRIS Pharma, a…
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA® December 31, 2020 LYON, France – NETRIS Pharma, a…
NETRIS Pharma will attend the Bio Partnering @ JPM conference that will take place Virtual (Jan 11th-15th, 2021). Our team members will be pleased to meet with you and discuss…
December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m…
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…
NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…